GlucoTrack (GCTK) Competitors $7.42 -0.24 (-3.13%) Closing price 04:00 PM EasternExtended Trading$7.41 -0.01 (-0.13%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GCTK vs. XAIR, INBS, DHAI, MHUA, BTCY, WOK, LYRA, PAVM, CODX, and SSKNShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Beyond Air (XAIR), Intelligent Bio Solutions (INBS), DIH Holding US (DHAI), Meihua International Medical Technologies (MHUA), Biotricity (BTCY), WORK Medical Technology Group (WOK), Lyra Therapeutics (LYRA), PAVmed (PAVM), Co-Diagnostics (CODX), and Strata Skin Sciences (SSKN). These companies are all part of the "medical equipment" industry. GlucoTrack vs. Its Competitors Beyond Air Intelligent Bio Solutions DIH Holding US Meihua International Medical Technologies Biotricity WORK Medical Technology Group Lyra Therapeutics PAVmed Co-Diagnostics Strata Skin Sciences GlucoTrack (NASDAQ:GCTK) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Does the media refer more to GCTK or XAIR? In the previous week, Beyond Air had 6 more articles in the media than GlucoTrack. MarketBeat recorded 8 mentions for Beyond Air and 2 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 1.35 beat Beyond Air's score of 0.50 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beyond Air 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, GCTK or XAIR? GlucoTrack has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Is GCTK or XAIR more profitable? GlucoTrack has a net margin of 0.00% compared to Beyond Air's net margin of -1,258.46%. GlucoTrack's return on equity of 0.00% beat Beyond Air's return on equity.Company Net Margins Return on Equity Return on Assets GlucoTrackN/A N/A -544.87% Beyond Air -1,258.46%-233.96%-113.92% Which has better valuation & earnings, GCTK or XAIR? GlucoTrack has higher earnings, but lower revenue than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlucoTrackN/AN/A-$22.60M-$56.60-0.13Beyond Air$3.70M3.74-$46.62M-$15.80-0.20 Do insiders & institutionals hold more shares of GCTK or XAIR? 10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 12.9% of GlucoTrack shares are owned by company insiders. Comparatively, 19.4% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer GCTK or XAIR? Beyond Air has a consensus price target of $23.67, suggesting a potential upside of 639.58%. Given Beyond Air's stronger consensus rating and higher possible upside, analysts plainly believe Beyond Air is more favorable than GlucoTrack.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Beyond Air 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 SummaryBeyond Air beats GlucoTrack on 11 of the 16 factors compared between the two stocks. Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.66M$10.55B$5.70B$9.51BDividend YieldN/A2.00%4.69%4.01%P/E Ratio-0.1317.0728.0720.05Price / SalesN/A29.18448.5799.42Price / CashN/A23.0336.2258.56Price / Book-0.013.698.665.87Net Income-$22.60M$234.77M$3.25B$258.55M7 Day Performance27.27%6.32%4.20%2.23%1 Month Performance-5.36%8.39%10.82%12.76%1 Year Performance-99.56%-13.51%34.70%19.36% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrack0.4064 of 5 stars$7.42-3.1%N/A-99.5%$3.66MN/A-0.135XAIRBeyond Air4.5544 of 5 stars$3.40+2.4%$23.67+596.1%-71.3%$14.34M$3.70M-0.2270High Trading VolumeINBSIntelligent Bio Solutions1.0351 of 5 stars$2.25+10.8%N/A+28.4%$14.03M$3.11M0.0010Positive NewsGap UpDHAIDIH Holding US0.2869 of 5 stars$0.26-11.0%N/A-91.0%$13.95M$64.47M-0.87N/AGap DownHigh Trading VolumeMHUAMeihua International Medical Technologies0.9642 of 5 stars$0.41-5.4%N/A-62.3%$13.78M$96.90M0.00620BTCYBiotricityN/A$0.51+6.3%N/A-34.7%$12.71M$12.06M-0.4740Analyst RevisionGap UpWOKWORK Medical Technology GroupN/A$0.78-4.8%N/AN/A$11.96M$11.51M0.00226Positive NewsGap UpLYRALyra Therapeutics3.1409 of 5 stars$8.20+0.6%$100.00+1,119.5%-43.9%$10.80M$1.19M-0.1450Positive NewsPAVMPAVmed4.3964 of 5 stars$0.59-1.5%$19.00+3,131.3%-43.7%$10.20M$2.99M0.8390Positive NewsCODXCo-Diagnostics4.3256 of 5 stars$0.29+3.9%$5.50+1,768.2%-76.1%$9.51M$3.91M-0.25100High Trading VolumeSSKNStrata Skin Sciences3.0689 of 5 stars$2.14-3.2%$6.00+180.4%-39.9%$9.22M$33.56M-0.94120High Trading Volume Related Companies and Tools Related Companies XAIR Alternatives INBS Alternatives DHAI Alternatives MHUA Alternatives BTCY Alternatives WOK Alternatives LYRA Alternatives PAVM Alternatives CODX Alternatives SSKN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GCTK) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.